Skip to main content
. 2020 Dec 4;40(2):e106123. doi: 10.15252/embj.2020106123

Figure 6. BCL9L highly expressed in soft tumor cells from cancer patients.

Figure 6

  1. The stiffness of primary breast (HBC, n = 3) and colon (HCC, n = 3) cancer cells screened from the outlet or backflow inlet was measured by AFM. n = 100 from each patient.
  2. The correlation between the percentage of soft primary tumor cells from patients with breast (n = 11) or colon (n = 23) cancer and the grade of breast or colon cancer, respectively.
  3. The stiff and soft tumor cells were isolated from 3 patients with breast cancer and stained with anti‐BCL9L antibody. The expression of BCL9L was observed under confocal microscope. Scale bar, 10 μm.
  4. The tissue sections from 6 melanoma patients with high grades of cancer and 3 melanoma patients with low grade of malignancy were immunohistochemical staining with anti‐BCL9L antibody. Scale bar, 50 μm.
  5. The correlation between the expression of BCL9L from 18 patients with melanoma and the grade of melanoma.
  6. Overall survival compared with the BCL9L level in patients with breast cancer (BRCA, n = 536) or melanoma (n = 376).

Data information: Mann–Whitney test (A), paired Student’s t‐test (C), Pearson’s correlation test (B and E) or Log‐rank survival analysis (F). The data represent mean ± SD.